ArticleScientific reports2019
Internalization, distribution, and activity of peptide H2 against the intracellular multidrug-resistant bovine mastitis-causing bacterium Staphylococcus aureus.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- In Vivo Assessment of Antimicrobial Potential of Synthetic ANLP-V3 Peptide for the Treatment of Mastitis in a Mouse Model.Current microbiology · 2026Article
- Multimodal molecular mechanisms of octanoic acid (OA) against recurrent mastitis causing pathogens.Applied microbiology and biotechnology · 2026Article
- Bovine mastitis, a worldwide impact disease: Prevalence, antimicrobial resistance, and viable alternative approaches.Veterinary and animal science · 2023Review
- Editorial: Community series in antimicrobial peptides: Molecular design, structure function relationship and biosynthesis optimization.Frontiers in microbiology · 2023Article
- Cell-Penetrating Antimicrobial Peptides with Anti-Infective Activity against Intracellular Pathogens.Antibiotics (Basel, Switzerland) · 2022Review
- The dual antimicrobial and immunomodulatory roles of host defense peptides and their applications in animal production.Journal of animal science and biotechnology · 2022Review
- Antibacterial peptide NZ2114-loaded hydrogel accelerates Staphylococcus aureus-infected wound healing.Applied microbiology and biotechnology · 2022Article
- Pharmacokinetics and Pharmacodynamics of Fungal Defensin NZX AgainstFrontiers in microbiology · 2022Article
- Effect of Two Different Drug-ResistantFrontiers in veterinary science · 2022Article
- Effect of NZ2114 againstFrontiers in microbiology · 2022Article
- Advances in therapeutic and managemental approaches of bovine mastitis: a comprehensive review.The veterinary quarterly · 2021Review
- A recombinant fungal defensin-like peptide-P2 combats Streptococcus dysgalactiae and biofilms.Applied microbiology and biotechnology · 2021Article
- Deciphering the Antibacterial Role of Peptide FromFrontiers in microbiology · 2021Article
- Marine Peptide-N6NH2 and Its Derivative-GUON6NH2 Have Potent Antimicrobial Activity Against IntracellularFrontiers in microbiology · 2021Article
- A Review on the Use of Antimicrobial Peptides to Combat Porcine Viruses.Antibiotics (Basel, Switzerland) · 2020Review
- Therapeutic potential of a designed CSαβ peptide ID13 in Staphylococcus aureus-induced endometritis of mice.Applied microbiology and biotechnology · 2020Article
- Hederacoside-C Inhibition of Staphylococcus aureus-Induced Mastitis via TLR2 & TLR4 and Their Downstream Signaling NF-κB and MAPKs Pathways In Vivo and In Vitro.Inflammation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bovine mastitis is mainly caused by Staphylococcus aureus, which is difficult to eliminate, prone to escape from antibacterial agents, and may cause recurring infections due to the intracellular nature of its infection and multidrug resistance. In this study, the intracellular activities of the NZ2114 derivative peptide H18R (H2) against methicillin-resistant S. aureus (MRSA) and multidrug-resistant bovine S. aureus strains were investigated in bovine mammary epithelial MAC-T cells and mouse mammary glands. The minimum inhibitory concentrations of H2 against S. aureus were 0.5‒1 μg/ml; H2 displayed a lower cytotoxicity than its parental peptide NZ2114 (survival rates of MAC-T cells: 100% [H2 treatment] vs 60.7% [NZ2114 (256 μg/ml) treatment]). H2 was internalized into MAC-T cells mainly via clathrin-mediated endocytosis, and distributed in the cytoplasm. The intracellular inhibition rates against MRSA ATCC43300, the mastitis isolates S. aureus CVCC 3051 and E48 were above 99%, 99%, and 94%, respectively; these were higher than those in case of vancomycin (23-47%). In the mouse model of S. aureus E48-induced mastitis, after treatment with 100 μg of H2 and vancomycin, bacterial numbers in each mammary gland were reduced by 3.96- and 1.59-log CFU, respectively. Additionally, similar to NZ2114 and vancomycin, H2 alleviated the histopathological damage of the mammary tissue and polymorphonuclear neutrophil infiltration in the alveoli. These results suggest that H2 can be used as a safe and effective candidate for treating S. aureus-induced mastitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.